Klk8 Antibody

What is KLK8 and what are its primary biological functions?

KLK8 (Kallikrein 8), also known as Neuropsin, is a serine protease capable of degrading multiple proteins including casein, fibrinogen, kininogen, fibronectin, and collagen type IV. It plays crucial roles in neural function by cleaving L1CAM in response to increased neural activity and inducing neurite outgrowth and fasciculation of cultured hippocampal neurons. In the central nervous system, KLK8 is involved in the formation and maturation of orphan and small synaptic boutons in the Schaffer-collateral pathway, regulates Schaffer-collateral long-term potentiation in the hippocampus, and is required for memory acquisition and synaptic plasticity . Beyond neuronal functions, KLK8 participates in skin desquamation, keratinocyte proliferation, and plays a role in the secondary phase of pathogenesis following spinal cord injury .

What types of KLK8 antibodies are available for research applications?

Researchers have access to several types of KLK8 antibodies optimized for different experimental applications. These include polyclonal antibodies such as rabbit polyclonal KLK8 antibodies suitable for Western blotting (WB) and immunohistochemistry with paraffin-embedded tissues (IHC-P) . Monoclonal antibodies are also available, including mouse monoclonal IgG1κ antibodies that can be used for Western blotting, immunohistochemistry, ELISA, and activity assays . For higher specificity applications, recombinant monoclonal antibodies such as rabbit recombinant monoclonal KLK8 antibodies have been developed with validated reactivity for human samples . When selecting an antibody, researchers should consider the specific epitope recognition, host species, and validated applications to ensure optimal experimental outcomes.

What are the common applications for KLK8 antibodies in neuroscience research?

In neuroscience research, KLK8 antibodies serve multiple experimental purposes. They are frequently employed to study synaptic plasticity mechanisms, as KLK8 regulates Schaffer-collateral long-term potentiation in the hippocampus . Immunohistochemistry with KLK8 antibodies allows visualization of protein expression patterns in brain tissue sections, particularly in regions involved in memory formation. Western blotting applications enable quantification of KLK8 expression levels in different brain regions or under various experimental conditions . KLK8 antibodies are also valuable tools for investigating neurite outgrowth and fasciculation processes in cultured hippocampal neurons, as well as examining the protein's role in neuronal recovery following spinal cord injury . When combined with electrophysiological techniques, KLK8 immunolabeling helps correlate protein expression with functional synaptic measurements.

How should researchers validate KLK8 antibody specificity before experimental use?

Proper validation of KLK8 antibody specificity is essential for generating reliable results. A comprehensive validation protocol should include:

• Western blot analysis: Run samples from tissues known to express KLK8 (e.g., hippocampus, skin) alongside negative control tissues. Verify that the antibody detects bands at the expected molecular weight (approximately 28 kDa for KLK8) .

• Recombinant protein controls: Test the antibody against purified recombinant KLK8 protein to confirm direct binding .

• Knockout/knockdown validation: Where possible, validate using samples from KLK8 knockout animals or cells with KLK8 knockdown to confirm signal disappearance.

• Peptide competition assay: Pre-incubate the antibody with excess immunizing peptide to demonstrate signal reduction/elimination in subsequent applications.

• Cross-reactivity assessment: Test against related kallikreins (especially KLK4, KLK10, and KLK14) to ensure selectivity for KLK8.

• Multiple antibody comparison: Use at least two different KLK8 antibodies targeting different epitopes to verify consistent localization patterns.

This systematic validation approach will establish confidence in antibody specificity before proceeding with experimental applications.

What are the optimal sample preparation protocols for detecting KLK8 in different tissue types?

Sample preparation protocols should be tailored to the specific tissue type and experimental application:

For brain tissue samples (Western blotting):

• Dissect fresh tissue and immediately flash-freeze in liquid nitrogen

• Homogenize in ice-cold RIPA buffer containing protease inhibitor cocktail

• Sonicate briefly (3-5 pulses at 30% amplitude)

• Centrifuge at 14,000×g for 15 minutes at 4°C

• Collect supernatant and determine protein concentration

• Denature samples with loading buffer at 95°C for 5 minutes

For paraffin-embedded tissue sections (IHC-P):

• Fix tissue in 10% neutral-buffered formalin for 24-48 hours

• Process tissue through graded alcohols and xylene

• Embed in paraffin and section at 4-6 μm thickness

• Perform heat-induced epitope retrieval using citrate buffer (pH 6.0)

• Block endogenous peroxidase activity with 3% H₂O₂

• Apply primary KLK8 antibody at optimized concentration (e.g., 20 μg/ml for some antibodies)

• Detect using appropriate secondary antibody and DAB staining

For cultured cells:

• Wash cells with PBS and lyse directly in sample buffer

• Sonicate briefly to shear DNA and reduce viscosity

• Centrifuge at 14,000×g for 10 minutes

• Collect supernatant for Western blotting applications

These protocols should be optimized for each specific KLK8 antibody and tissue type to maximize signal-to-noise ratio.

What controls should be included when performing immunohistochemistry with KLK8 antibodies?

A robust immunohistochemistry experiment with KLK8 antibodies should include several critical controls:

• Primary antibody omission control: Process tissue sections through the entire protocol but substitute antibody diluent for primary KLK8 antibody to assess non-specific binding of secondary antibodies or detection reagents.

• Isotype control: Substitute the KLK8 antibody with a non-specific antibody of the same isotype (e.g., rabbit IgG for rabbit polyclonal antibodies or mouse IgG1κ for corresponding monoclonal antibodies) at the same concentration to identify non-specific binding .

• Concentration gradient: Test a range of primary antibody concentrations to determine optimal signal-to-noise ratio. For some KLK8 antibodies, 20 μg/ml has been validated for pancreatic tissue .

• Positive control tissue: Include tissue sections known to express KLK8 (e.g., pancreas, hippocampus) to verify staining protocol efficacy .

• Negative control tissue: Include tissue sections with minimal or no KLK8 expression to confirm specificity.

• Peptide competition control: Pre-incubate antibody with immunizing peptide to demonstrate specific binding.

• Multiple detection methods: When possible, confirm findings using both chromogenic (e.g., DAB) and fluorescent detection systems.

These controls collectively ensure that observed staining patterns represent genuine KLK8 expression rather than technical artifacts.

How can researchers effectively study KLK8's role in cancer progression using antibody-based approaches?

Recent research has revealed KLK8's significant role in cancer biology, particularly in colorectal cancer (CRC). To effectively investigate this role, researchers should employ a multi-faceted antibody-based approach:

• Expression profiling: Use validated KLK8 antibodies for immunohistochemical analysis of tissue microarrays containing tumor and matched normal tissues to assess expression patterns. Correlate staining intensity with clinical parameters such as tumor stage, metastatic status, and patient survival .

• Functional mechanistic studies: After KLK8 overexpression or knockdown in cancer cell lines, use Western blotting with KLK8 antibodies to confirm altered expression, then examine downstream effects on EMT markers (E-cadherin, N-cadherin, vimentin) to establish pathway connections .

• In vivo tumor models: Generate xenograft models using KLK8-modified cancer cells, then use antibody-based detection methods to analyze tumor growth characteristics and metastatic potential .

• Pathway inhibition studies: Combine KLK8 antibody detection with targeted inhibitors (e.g., PAR-1 antagonist SCH79797) to elucidate mechanistic pathways. Monitor changes in tumor proliferation, migration, and invasion following inhibitor treatment .

• Co-immunoprecipitation: Use KLK8 antibodies to pull down protein complexes and identify interaction partners that may mediate its effects on cancer progression.

This comprehensive approach allows researchers to establish both correlative and causative relationships between KLK8 and cancer progression, potentially identifying new therapeutic targets.

What are the key considerations when using KLK8 antibodies for studying neuronal plasticity and memory formation?

Investigating KLK8's role in neuronal plasticity requires careful experimental design with several critical considerations:

• Temporal expression analysis: KLK8 expression fluctuates in response to neuronal activity. Use timed tissue collection after learning tasks or LTP induction, followed by antibody detection to correlate expression changes with specific phases of memory formation.

• Activity-dependent regulation: Combine electrophysiological recordings with post-hoc immunohistochemistry using KLK8 antibodies to directly correlate electrical activity with protein expression at the cellular level .

• Substrate interaction assessment: KLK8 cleaves neural adhesion molecule L1CAM and potentially other substrates. Use co-immunoprecipitation with KLK8 antibodies followed by mass spectrometry to identify novel substrates in hippocampal tissue .

• Subcellular localization: Perform high-resolution confocal or super-resolution microscopy with KLK8 antibodies to determine precise subcellular localization at synaptic structures, particularly in Schaffer-collateral pathway synapses .

• Behavioral correlates: Following behavioral tests assessing learning and memory, use KLK8 antibodies to quantify expression in specific hippocampal regions and correlate with behavioral performance.

• Pharmacological manipulation: Apply KLK8 inhibitors or recombinant KLK8 to hippocampal slices, then use antibodies to assess effects on downstream signaling pathways related to synaptic plasticity.

These approaches allow researchers to establish mechanistic links between KLK8 activity and specific aspects of neuronal plasticity and memory formation.

How can researchers integrate KLK8 antibody-based detection with other molecular techniques for comprehensive pathway analysis?

Integrating multiple molecular techniques with KLK8 antibody detection creates a powerful system for comprehensive pathway analysis:

• Multiplex immunofluorescence: Combine KLK8 antibodies with antibodies against downstream effectors (e.g., PAR-1) or pathway components to visualize spatial relationships and co-expression patterns within tissue sections .

• Single-cell analysis pipeline:

  • Perform single-cell sorting based on KLK8 expression using antibody-based methods

  • Conduct RNA-seq on sorted populations to identify transcriptomic signatures

  • Validate findings at protein level using KLK8 antibodies in conjunction with antibodies against identified targets

• CRISPR-based functional genomics:

  • Use CRISPR to modify KLK8 or pathway components

  • Validate genomic modifications using antibody-based detection

  • Assess functional consequences using cellular assays

  • Correlate phenotypic changes with molecular alterations using antibody detection

• Proximity ligation assay (PLA): Use KLK8 antibodies in conjunction with antibodies against suspected interaction partners to visualize and quantify protein-protein interactions at endogenous levels within cells.

• ChIP-seq integration: For transcription factors regulated downstream of KLK8 signaling, combine ChIP-seq with Western blot validation using KLK8 antibodies to link KLK8 activity to transcriptional regulation.

This integrated approach provides multi-level evidence for KLK8's role in cellular pathways, from direct protein interactions to broader transcriptional networks.

How should researchers address weak or nonspecific signals when using KLK8 antibodies?

When encountering weak or nonspecific signals with KLK8 antibodies, researchers should systematically optimize their protocols:

• Antibody concentration optimization:

  • Perform titration experiments with increasing antibody concentrations

  • For Western blotting, test concentrations ranging from 0.5-5 μg/ml

  • For IHC-P, test concentrations from 1-25 μg/ml

• Sample preparation refinement:

  • Ensure complete protein denaturation for Western blotting

  • Test different lysis buffers (RIPA, NP-40, Triton X-100) to maximize protein extraction

  • For tissue sections, optimize fixation duration and antigen retrieval methods

• Blocking optimization:

  • Test different blocking solutions (BSA, normal serum, commercial blockers)

  • Increase blocking duration to reduce background

  • Include detergents (0.1-0.3% Triton X-100) to reduce nonspecific binding

• Signal amplification strategies:

  • Consider biotin-streptavidin amplification systems

  • Use polymer-based detection systems for IHC

  • Employ enhanced chemiluminescence substrates for Western blotting

• Cross-reactivity elimination:

  • Pre-absorb antibodies with related proteins

  • Optimize washing steps (increase number, duration, or detergent concentration)

  • Use highly purified antibody preparations when available

• Alternative antibody evaluation:

  • Test different KLK8 antibodies targeting distinct epitopes

  • Compare polyclonal versus monoclonal antibodies for your application

  • Consider recombinant monoclonal antibodies for highest specificity

Systematic application of these troubleshooting approaches can significantly improve signal quality and specificity.

What approaches should be used to quantify and interpret KLK8 expression levels in complex tissue samples?

Accurate quantification of KLK8 expression in complex tissues requires rigorous methodological approaches:

• Western blot quantification protocol:

  • Include recombinant KLK8 protein standards at known concentrations

  • Normalize KLK8 signal to multiple housekeeping proteins (β-actin, GAPDH, β-tubulin)

  • Use fluorescent secondary antibodies for wider linear dynamic range

  • Perform technical replicates (minimum of 3) and biological replicates (minimum of 3)

  • Apply statistical analysis appropriate for sample size and distribution

• Immunohistochemical scoring methods:

  • Implement semi-quantitative scoring systems (H-score, Allred score)

  • Use digital image analysis software for objective quantification

  • Employ multiple blinded observers to reduce scoring bias

  • Validate scoring consistency with intraclass correlation coefficients

• Single-cell resolution approaches:

  • Use flow cytometry with KLK8 antibodies for high-throughput single-cell quantification

  • Apply fluorescence intensity calibration beads to standardize measurements

  • Complement with imaging flow cytometry to correlate signal with morphological features

• Context-dependent interpretation:

  • Consider regional variations within tissues (especially in brain samples)

  • Account for cell type heterogeneity using co-staining with cell type-specific markers

  • Interpret KLK8 levels relative to physiological or pathological context

• Meta-analysis framework:

  • Compare quantification results across multiple detection methods

  • Cross-validate findings with publicly available transcriptomic data

  • Establish confidence intervals for normal expression ranges in specific tissues

These approaches collectively enable robust quantification and contextual interpretation of KLK8 expression patterns.

How can researchers reconcile contradictory results between different KLK8 antibodies or detection methods?

When faced with contradictory results between different KLK8 antibodies or detection methods, researchers should pursue a systematic reconciliation approach:

• Epitope mapping analysis:

  • Determine the exact epitopes recognized by each antibody

  • Consider whether post-translational modifications might affect epitope accessibility

  • Evaluate whether detected discrepancies might reflect different KLK8 isoforms or activation states

• Cross-validation with orthogonal methods:

  • Complement antibody-based detection with mRNA analysis (qPCR, RNA-seq)

  • Verify findings with activity-based assays that measure KLK8 enzymatic function

  • Consider mass spectrometry-based proteomics as an antibody-independent validation

• Technical variable assessment:

  • Standardize sample preparation across all detection methods

  • Ensure identical lot numbers of antibodies are used throughout studies

  • Control for environmental variables (temperature, incubation time)

• Sensitivity and specificity characterization:

  • Determine detection limits for each antibody/method

  • Evaluate false positive rates using appropriate negative controls

  • Assess dynamic range to ensure measurements occur within linear response range

• Biological variable consideration:

  • Account for circadian rhythms or activity-dependent fluctuations

  • Control for age, sex, and genetic background variables

  • Consider stress or handling effects on KLK8 expression

• Integrative data interpretation:

  • Weigh evidence based on methodological rigor

  • Consider consensus findings across multiple approaches

  • Develop testable hypotheses to resolve persistent contradictions

This systematic approach transforms contradictory results from a limitation into an opportunity for deeper mechanistic insights.

How might KLK8 antibodies be utilized to investigate the protein's role in neurological disorders?

KLK8's involvement in synaptic plasticity and memory formation suggests potential roles in neurological disorders. Researchers can leverage KLK8 antibodies to investigate these connections through:

• Post-mortem tissue analysis:

  • Compare KLK8 expression patterns in brain regions from patients with Alzheimer's disease, schizophrenia, or epilepsy versus matched controls

  • Correlate expression levels with disease severity markers

  • Examine co-localization with disease-associated proteins (amyloid-β, tau, α-synuclein)

• Animal model characterization:

  • Track KLK8 expression changes throughout disease progression in genetic or induced models of neurodegeneration

  • Correlate biochemical changes with behavioral deficits

  • Test whether KLK8 modulation affects disease phenotypes

• Cell-type specific analysis:

  • Use multiplex immunofluorescence to determine whether KLK8 alterations occur in specific neuronal subtypes or glial populations

  • Investigate cell-autonomous versus non-cell-autonomous effects using conditional genetic approaches

• Biomarker development pipeline:

  • Assess KLK8 levels in cerebrospinal fluid using antibody-based ELISA

  • Correlate CSF KLK8 with clinical measures and disease progression

  • Evaluate sensitivity and specificity for diagnostic applications

• Therapeutic target validation:

  • Use KLK8 antibodies to monitor target engagement in preclinical studies

  • Assess whether pharmacological modulation of KLK8 activity affects disease-relevant endpoints

  • Develop function-blocking antibodies as potential therapeutic agents

These approaches could establish KLK8 as a novel diagnostic marker or therapeutic target for neurological disorders.

What new methodologies are being developed to enhance specificity and sensitivity of KLK8 detection in research settings?

Several cutting-edge methodologies are emerging to improve KLK8 detection:

• Recombinant antibody engineering:

  • Single-chain variable fragment (scFv) antibodies with enhanced specificity for KLK8

  • Bispecific antibodies targeting KLK8 and its substrate for interaction studies

  • Affinity-matured recombinant antibodies with sub-nanomolar binding constants

• Advanced imaging techniques:

  • Super-resolution microscopy (STORM, PALM) for nanoscale localization of KLK8

  • Expansion microscopy to physically enlarge samples for improved spatial resolution

  • Lattice light-sheet microscopy for rapid 3D imaging of KLK8 dynamics in living neurons

• Proximity-based detection systems:

  • Split-GFP complementation assays for visualizing KLK8-substrate interactions

  • FRET-based reporters to monitor KLK8 enzymatic activity in real-time

  • HaloTag fusion proteins for pulse-chase analysis of KLK8 trafficking

• Single-molecule detection approaches:

  • Single-molecule pull-down (SiMPull) for analyzing KLK8 protein complexes

  • Stochastic optical reconstruction microscopy with point accumulation for imaging in nanoscale topography (PAINT) for single-molecule localization

  • Optical tweezers combined with fluorescence microscopy for force measurements during KLK8-substrate interactions

• Microfluidic and digital detection platforms:

  • Digital ELISA for ultrasensitive KLK8 quantification

  • Microfluidic antibody capture for single-cell proteomic analysis

  • Droplet digital PCR coupled with proximity ligation assay for absolute quantification

These emerging technologies promise to reveal previously undetectable aspects of KLK8 biology and function.

How does KLK8's role in epithelial-mesenchymal transition suggest new applications for KLK8 antibodies in cancer research?

Recent discoveries about KLK8's involvement in epithelial-mesenchymal transition (EMT) open new avenues for antibody applications in cancer research:

• EMT biomarker development:

  • Use KLK8 antibodies alongside established EMT markers (E-cadherin, vimentin) to create a comprehensive EMT signature panel

  • Develop multiplex immunohistochemistry protocols to simultaneously detect KLK8 and EMT markers in tumor samples

  • Correlate KLK8 expression with EMT status and clinical outcomes in diverse cancer types

• Therapeutic resistance mechanisms:

  • Investigate whether KLK8-driven EMT contributes to chemotherapy or immunotherapy resistance

  • Use antibody-based detection to monitor KLK8 expression changes during treatment

  • Test whether KLK8 inhibition can reverse EMT and restore treatment sensitivity

• Metastasis research applications:

  • Monitor KLK8 expression in circulating tumor cells using antibody-based liquid biopsy approaches

  • Analyze KLK8 levels in primary tumors versus metastatic lesions

  • Investigate whether KLK8 antibodies can detect early EMT changes preceding metastatic spread

• Mechanistic pathway dissection:

  • Use KLK8 antibodies to identify the protease-activated receptor (PAR) dependency of EMT in different cancer types

  • Investigate whether SCH79797 (PAR-1 antagonist) effects on tumor reduction are linked to KLK8 expression levels

  • Determine whether combined targeting of KLK8 and PAR-1 produces synergistic anti-tumor effects

• Therapeutic antibody development:

  • Explore function-blocking antibodies against KLK8 as potential EMT inhibitors

  • Develop antibody-drug conjugates targeting KLK8-expressing cancer cells

  • Create bispecific antibodies targeting KLK8 and immune effector cells for enhanced tumor targeting

These applications could transform KLK8 from a biomarker into a therapeutic target for metastasis prevention.

What are the most promising future directions for KLK8 antibody development and application?

The future of KLK8 antibody technology holds several promising directions:

• Engineered antibody formats:

  • Development of activity-state specific antibodies that distinguish between pro-KLK8 and active KLK8

  • Creation of conformation-sensitive antibodies that report on structural changes upon substrate binding

  • Engineering of intrabodies for tracking endogenous KLK8 in living cells

• Therapeutic applications:

  • Function-blocking antibodies for neurological disorders with KLK8 overactivation

  • Anti-KLK8 antibody therapy for metastatic colorectal cancer targeting the EMT process

  • Antibody-directed enzyme prodrug therapy using KLK8's proteolytic activity

• Diagnostic implementations:

  • Ultrasensitive point-of-care tests for KLK8 detection in cerebrospinal fluid or blood

  • Multiplex antibody arrays including KLK8 and related kallikreins for cancer profiling

  • Imaging agents using radiolabeled or fluorescently labeled KLK8 antibodies for tumor visualization

• Research tool expansion:

  • Substrate-specific antibodies that recognize KLK8-cleaved proteins

  • Compartment-specific detection systems for monitoring KLK8 trafficking

  • Antibody-based optogenetic tools for spatiotemporal control of KLK8 function

These innovations will expand both basic research capabilities and clinical applications of KLK8 antibody technology.

What interdisciplinary approaches are integrating KLK8 antibody research with other cutting-edge fields?

Exciting interdisciplinary approaches are emerging at the intersection of KLK8 antibody research and other fields:

• Neuroscience + Cancer Biology:

  • Investigating shared KLK8-dependent mechanisms between neural plasticity and cancer cell invasion

  • Exploring whether neural signaling affects KLK8 expression in brain tumors

  • Applying lessons from neural KLK8 functions to understand cancer cell migration

• Proteomics + Systems Biology:

  • Creating comprehensive KLK8 interactome maps using antibody-based pull-downs coupled with mass spectrometry

  • Modeling the impact of KLK8 activity on protease networks using quantitative proteomics

  • Developing integrated multi-omics approaches with KLK8 antibody-based proteomics as a cornerstone

• Nanotechnology + Antibody Engineering:

  • Designing KLK8 antibody-conjugated nanoparticles for targeted drug delivery

  • Creating nanobiosensors for real-time monitoring of KLK8 activity in living systems

  • Developing lab-on-a-chip devices with immobilized KLK8 antibodies for rapid diagnostics

• Computational Biology + Structural Immunology:

  • Employing AI-driven epitope prediction to design improved KLK8 antibodies

  • Using molecular dynamics simulations to optimize antibody-KLK8 interactions

  • Implementing machine learning to predict antibody performance in different applications

• Regenerative Medicine + Neurology:

  • Investigating KLK8's role in neural regeneration after injury

  • Developing antibody-based therapies targeting KLK8 to promote functional recovery

  • Creating tissue-engineered models with KLK8 detection systems to study repair processes